# US 8,771,706 B2 · Anti-RSV immunogens and methods of immunization > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 8,771,706 B2 - Document ID: US8771706B2 - Status: Granted - Kind: B2 - Application number: 13/763,822 - Filed: 2013-02-11 - Published: 2013-05-30 - Granted: 2014-07-08 - Earliest claimed: 2009-08-04 - Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services - Applicants: The United States of America being represented by the Secretary of the Department of - Inventors: Larry J. Anderson; Lia M. Haynes; Ralph A. Tripp - Web page: https://patentgrep.com/patent/US8771706B2 ## CPC - C07K 14/135: Respiratory syncytial virus - A61K 39/12: Viral antigens - A61K 39/155: Paramyxoviridae, e.g. parainfluenza virus - A61P 31/14: for RNA viruses - A61P 37/04: Immunostimulants - C07K 14/005: from viruses - A61K 2039/5252: {inactivated (killed)} - A61K 2039/545: {characterised by the dose, timing or administration schedule} - A61K 2039/555: {characterised by a specific combination antigen/adjuvant} - A61K 2039/55505: {Inorganic adjuvants} - A61K 2039/6081: {Albumin; Keyhole limpet haemocyanin [KLH]} - C12N 2760/18522: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes - C12N 2760/18534: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein - C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00) - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS - C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00) ## Abstract Immunogenic polypeptides corresponding to one or more RSV G glycoproteins, or analogs thereof, are provided as components of vaccines. The inventive compositions are useful as both a prophylactic and therapeutic for the prevention and treatment of RSV infections and associated pulmonary or other diseases. The inventive immunogens include regions of the RSV G protein, specifically, amino acid residues 164-176 of RSV G A2 protein or analogs thereof. This inventive immunogen is operable alone or in combination with other polypeptides such as the RSV G protein amino acid residues 155-206, or other vaccines such as live RSV vaccines, or inactivated RSV vaccines or immunogenic analogs thereof. ## Claims ### Claim 1 A respiratory syncytial virus vaccine comprising an isolated immunogen that elicits a protective immune response that protects against an RSV vaccine enhanced RSV immune response said immunogen consisting of an amino acid sequence, said amino acid sequence consisting of the amino acids of: (i) amino acid position 163 to amino acid position 190 of SEQ ID NO: 8, amino acid position 163 to amino acid position 190 of SEQ ID NO. 7, or amino acid position 163 to amino acid position 190 of SEQ ID NO. 1; (ii) amino acid position 155 to amino acid position 206 of SEQ ID NO: 7, amino acid position 155 to amino acid position 206 of SEQ ID NO: 1, or amino acid position 155 to amino acid position 206 of SEQ ID NO: 8; or a combination thereof. ### Claim 2 (depends on 1) The vaccine of claim 1 wherein said immunogen further comprises a tag suitable for isolation of the immunogen. ### Claim 3 (depends on 1) The vaccine of claim 1 wherein said vaccine consists of the polypeptide of SEQ ID NO: 4 or 5. ### Claim 4 (depends on 3) The vaccine of claim 3 further comprising a second immunogen consisting of a polypeptide of SEQ ID NO: 3 or 6. ### Claim 5 (depends on 1) The vaccine of claim 1 wherein said immunogen consists of a polypeptide of SEQ ID NO: 4 or SEQ ID NO: 6. ### Claim 6 A respiratory syncytial virus vaccine comprising an isolated immunogen that protects from an aberrant or enhanced response to an RSV vaccine in a human subject, said immunogen consisting of an amino acid sequence consisting of the amino acids of: (i) amino acid position 163 to amino acid position 190 of SEQ ID NO: 8, amino acid position 163 to amino acid position 190 of SEQ ID NO. 7, or amino acid position 163 to amino acid position 190 of SEQ ID NO. 1; (ii) amino acid position 155 to amino acid position 206 of SEQ ID NO: 7, amino acid position 155 to amino acid position 206 of SEQ ID NO: 1, or amino acid position 155 to amino acid position 206 of SEQ ID NO: 8; or a combination thereof; and an immunogenic carrier that promotes the immunogenicity of said immunogen, said immunogenic carrier coupled to said immunogen. ### Claim 7 (depends on 6) The vaccine of claim 6 wherein said immunogen is fused to a tag suitable for isolation of the immunogen. ### Claim 8 (depends on 6) The vaccine of claim 6 wherein said vaccine comprises an immunogen consisting of the polypeptide of SEQ ID NO: 4 or 5. ### Claim 9 (depends on 8) The vaccine of claim 8 further comprising a second immunogen consisting of a polypeptide of SEQ ID NO: 3 or 6 alone or coupled to an immunogenic carrier. ### Claim 10 (depends on 6) The vaccine of claim 6 wherein said vaccine comprises an immunogen consisting of the polypeptide of SEQ ID NO: 4 or SEQ ID NO: 6.